Analysts' Top 5 Price Targets of August 6, 2025
Reading Time: 3 minutes
Castle Biosciences [US14843C1053] Lake Street confirms Buy rating with a price target of $35 (77% upside potential) The molecular diagnostics company performed significantly better in the second quarter of 2025 than analysts had expected. As a result, the revenue forecast was raised from $287-297 million to $310-320 million for fiscal year 2025, which is also above the market consensus of $293.89 million. Notably, the growth of the two main products: DecisionDx-Melanoma and TissueCypher, was exceptional. Both tests exceeded volume expectations...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
